• Profile

Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists

Diabetes Research and Clinical Practice Feb 12, 2022

In Japanese patients with type 2 diabetes mellitus treated with sodium glucose co-transporter 2 inhibitors (SGLT2i), a lower renal composite outcome incidence was observed in comparison to glucagon-like peptide 1 receptor agonists (GLP1Ra)-treated patients.

  • By employing propensity score matching, patient outcomes after SGLT2i and GLP1Ra treatments were compared.

  • The renal composite outcome was defined as either progression of albuminuria status and/or >15% deterioration in estimated glomerular filtration rate (eGFR) per year.

  • SGLT2i-treated patients had significantly lower incidence of renal composite outcomes compared to GLP1Ra-treated patients (n = 15 [11%] and n = 27 [20%], respectively).

  • Significant differences in annual eGFR changes (mL/min/1.73 m <sup>2</sup> /year) were found between the two groups (−1.8 [95%CI, −2.7, −0.9] in SGLT2i-treated patients and −3.4 [95%CI, −4.6, −2.2] in GLP1Ra-treated patients).

  • Change in the urine albumin-to-creatinine ratio occurred due to a significant interaction between the presence or absence of a reduction in systolic blood pressure and the difference in treatments.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen